Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET for 30 days on the company's Investor Relations website.
Compugen, known for its pioneering work in computational target discovery, aims to showcase its latest developments and strategies to investors and industry professionals. This presentation offers an opportunity for stakeholders to gain insights into Compugen's progress in the competitive field of cancer immunotherapy.
Compugen (Nasdaq: CGEN), un'azienda di immunoterapia oncologica in fase clinica, ha annunciato la sua prossima presentazione virtuale alla 26esima Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. La presentazione sarà disponibile on-demand a partire da 9 settembre 2024, alle 7:00 AM ET per 30 giorni sul sito web delle Relazioni con gli Investitori della società.
Compugen, nota per il suo lavoro pionieristico nella scoperta di target computazionale, mira a mostrare i suoi ultimi sviluppi e strategie a investitori e professionisti del settore. Questa presentazione offre l'opportunità agli stakeholder di ottenere informazioni sui progressi di Compugen nel competitivo campo dell'immunoterapia oncologica.
Compugen (Nasdaq: CGEN), una empresa de inmunoterapia contra el cáncer en etapa clínica, anunció su próxima presentación virtual en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. La presentación estará disponible bajo demanda a partir del 9 de septiembre de 2024, a las 7:00 AM ET durante 30 días en el sitio web de Relaciones con Inversores de la compañía.
Compugen, conocida por su trabajo pionero en la descubrimiento de objetivos computacionales, tiene como objetivo exhibir sus últimos desarrollos y estrategias a inversionistas y profesionales de la industria. Esta presentación ofrece una oportunidad para que los interesados obtengan información sobre el progreso de Compugen en el competitivo campo de la inmunoterapia contra el cáncer.
Compugen (Nasdaq: CGEN), 임상 단계의 암 면역 치료 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 회의에서의 다가오는 가상 발표를 발표했습니다. 이 발표는 2024년 9월 9일 오전 7시 ET부터 30일 동안 회사의 투자자 관계 웹사이트에서 온디맨드로 제공됩니다.
계산적 타겟 발견 분야에서 선구적인 작업으로 알려진 Compugen은 최신 개발 및 전략을 투자자 및 업계 전문가에게 선보일 계획입니다. 이 발표는 이해관계자들이 암 면역 치료의 경쟁 분야에서 Compugen의 진행 상황에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Compugen (Nasdaq: CGEN), une entreprise d'immunothérapie contre le cancer en phase clinique, a annoncé sa prochaine présentation virtuelle lors de la 26e Conférence annuelle mondiale sur les investissements H.C. Wainwright. La présentation sera disponible à la demande à partir du 9 septembre 2024, à 7h00 ET pendant 30 jours sur le site web des relations avec les investisseurs de l'entreprise.
Compugen, connue pour son travail pionnier dans la découverte de cibles computationnelles, vise à présenter ses derniers développements et stratégies aux investisseurs et aux professionnels de l'industrie. Cette présentation offre aux parties prenantes l'opportunité d'obtenir des informations sur les avancées de Compugen dans le domaine concurrentiel de l'immunothérapie contre le cancer.
Compugen (Nasdaq: CGEN), ein Unternehmen für Immuntherapie im klinischen Stadium, hat seine bevorstehende virtuelle Präsentation auf der 26. jährlichen globalen Investitionskonferenz von H.C. Wainwright angekündigt. Die Präsentation wird ab 9. September 2024, um 7:00 Uhr ET für 30 Tage auf der Website für Investorenbeziehungen des Unternehmens on-demand verfügbar sein.
Compugen, bekannt für seine Pionierarbeit im Bereich der computergestützten Zielentdeckung, hat sich zum Ziel gesetzt, Investoren und Branchenfachleuten die neuesten Entwicklungen und Strategien vorzustellen. Diese Präsentation bietet den Stakeholdern die Möglichkeit, Einblicke in den Fortschritt von Compugen im wettbewerbsintensiven Bereich der Krebsimmuntherapie zu gewinnen.
- None.
- None.
HOLON,
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302233882.html
SOURCE Compugen Ltd.
FAQ
When is Compugen (CGEN) presenting at the H.C. Wainwright Global Investment Conference?
Where can I access Compugen's (CGEN) presentation from the H.C. Wainwright conference?
What is Compugen's (CGEN) primary focus as a company?
On which stock exchanges is Compugen (CGEN) listed?
